PAION AG

  • WKN: A0B65S
  • ISIN: DE000A0B65S3
  • Land: Deutschland

Nachricht vom 17.02.2017 | 15:08

DGAP-DD: PAION AG english


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

17.02.2017 / 15:07
The issuer is solely responsible for the content of this announcement.


1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Title: Dr.
First name: Mariola
Last name(s): Söhngen

2. Reason for the notification

a) Position / status
Person closely associated with:
Title: Dr.
First name: Wolfgang
Last name(s): Söhngen
Position: Member of the managing body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
PAION AG

b) LEI
529900CGHB9UWY40BU45 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Financial instrument linked to a share or a debt instrument
Description: Subscription rights with ISIN DE000A2AA4K2

b) Nature of the transaction
Donation of 656,094 subscription rights to Jonathan Söhngen; The transaction is not linked to the participation in a share option programme.

c) Price(s) and volume(s)
Price(s) Volume(s)
not numberable not numberable

d) Aggregated information
Price Aggregated volume
not numberable not numberable

e) Date of the transaction
2017-02-14; UTC+1

f) Place of the transaction
Outside a trading venue



17.02.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

Ergomed PLC: Kursziel angehoben

Die erfolgreiche Wirksamkeitsstudie von Lorediplon zeigt, dass Ergomed PLC eine sehr vielversprechende Co-Development-Pipeline hat. Eine mögliche vorzeitige Auslizenzierungen des Produkts würde dem Unternehmen signifikante Erfolgsbeteiligungen sichern. Deshalb und aufgrund der Anpassung der Wechselkurse erhöhen wir den fairen Wert der Ergomed-Aktie auf 3,41 € je Aktie. Das Rating bleibt KAUFEN.

Aktueller Webcast

XING AG

Preliminary Results 2016

23. Februar 2017

Aktuelle Research-Studie

HELMA Eigenheimbau AG

Original-Research: HELMA Eigenheimbau AG (von GBC AG): Kaufen

24. Februar 2017